# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123242
Filing Date
2024-11-07
Accepted
2024-11-07 16:00:30
Documents
51
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | crdf-20240930.htm iXBRL | 10-Q | 1526928
2 | EX-31.1 | crdf-ex31_1.htm | EX-31.1 | 13321
3 | EX-31.2 | crdf-ex31_2.htm | EX-31.2 | 13220
4 | EX-32.1 | crdf-ex32_1.htm | EX-32.1 | 6575
5 | EX-32.2 | crdf-ex32_2.htm | EX-32.2 | 6474
| Complete submission text file | 0000950170-24-123242.txt |  | 5965288

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | crdf-20240930.xsd | EX-101.SCH | 679094
53 | EXTRACTED XBRL INSTANCE DOCUMENT | crdf-20240930_htm.xml | XML | 1145342

Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35558 | Film No.: 241435343
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)